There are supply disruptions affecting various strengths of medicines licensed for the treatment of attention deficit hyperactivity disorder (ADHD). This has been caused by a combination of manufacturing issues and an increased global demand.
Affected brands and strengths are listed on the Central Alerting System, however it should be noted that remaining products cannot support an excessive increase in demand.
Prescribers may wish to utilise our recent Medicines Value Bulletin regarding methylphenidate XL tablets to find pharmacologically suitable alternatives if the regular medication is not available at this time.